Biocon revises preferential issue price to ₹376.41 per share
Biocon Limited revised the pricing for its preferential issue to ₹376.41 per share, with a floor price of ₹373.08, following advice from NSE and BSE. The company will issue 87,86,362 shares to Biocon Biologics shareholders at a swap ratio of 0.76159. A corrigendum was dispatched on May 29, 2026, and advertised in newspapers on May 30, 2026, with voting concluding on June 07, 2026.
*this image is generated using AI for illustrative purposes only.
Biocon Limited has revised the pricing structure for its preferential issue of equity shares, setting the floor price at ₹373.08 and the issue price at ₹376.41 per equity share. The company will issue 87,86,362 equity shares to shareholders of Biocon Biologics Limited (BBL) as part of a transaction to make BBL a wholly-owned subsidiary. The swap ratio has been fixed at 0.76159, meaning the company will issue 76.159 equity shares for every 100 equity shares of BBL held by the selling shareholders.
The revision follows advice from the National Stock Exchange of India Limited (NSE) and BSE Limited, which required the company to provide clarifications regarding the preferential issue. Consequently, the board approved amendments to the floor price, issue price, swap ratio, and the number of shares to be issued on May 28, 2026. The company issued a corrigendum to the postal ballot notice on May 28, 2026, and dispatched it electronically on May 29, 2026, to members registered as of May 01, 2026. Newspaper advertisements regarding the corrigendum were published in the Financial Express and Vijayavani on May 30, 2026.
Revised Pricing and Valuation
The floor price was determined based on the higher of the 90-day volume weighted average price (VWAP) of ₹373.08, the 10-day VWAP of ₹368.07, or the price determined by an independent registered valuer. Mr. Santosh Kumar Katla, an Independent Registered Valuer, certified the floor price at ₹373.08 per equity share in a report dated May 27, 2026. The final issue price of ₹376.41 includes a premium of ₹371.41 per equity share.
| Particulars | Details |
|---|---|
| 90-day VWAP | ₹373.08 per Equity Share |
| 10-day VWAP | ₹368.07 per Equity Share |
| Floor price | ₹373.08 per Equity Share |
| Issue Price | ₹376.41 per Equity Share |
| Number of shares to be issued | 87,86,362 |
| Swap Ratio | 0.76159 |
Shareholder Impact and Voting
The preferential issue will alter the company's shareholding pattern. While the promoter and promoter group holding will decrease slightly from 44.91% to 44.68%, the non-promoters' holding will increase from 55.09% to 55.32%. The total number of equity shares post-issue will rise to 1,62,96,94,135.
Votes already cast by members on the resolution prior to the receipt of this corrigendum remain valid. However, shareholders wishing to modify their votes in light of the new information may do so by emailing the scrutinizer at compliance@sreedharancs.com on or before 5:00 p.m. (IST) on June 07, 2026. The remote e-voting process commenced on May 09, 2026, and is scheduled to conclude on June 07, 2026. The corrigendum has been issued in compliance with Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Historical Stock Returns for Biocon
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.70% | -1.07% | +17.50% | +6.85% | +26.83% | +9.65% |
How will the market react to the revised pricing once the preferential issue is officially executed?
What impact will making Biocon Biologics a wholly-owned subsidiary have on Biocon's overall financial performance?
How might the slight decrease in promoter holding influence shareholder sentiment and corporate governance?
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
